- Home
- RELX vs TAK Comparison
RELX vs TAK Comparison
Compare RELX & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RELX | TAK |
|---|---|---|
| Founded | 1903 | 1781 |
| Country | United Kingdom | Japan |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.0B | 57.6B |
| IPO Year | 2007 | 2007 |
Fundamental Metrics
Financial Performance| Metric | RELX | TAK |
|---|---|---|
| Price | $34.21 | $18.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.0M | ★ 2.1M |
| Earning Date | 02-12-2026 | 05-13-2026 |
| Dividend Yield | 2.42% | ★ 3.24% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.72 | $0.16 |
| Revenue Next Year | $6.41 | $1.22 |
| P/E Ratio | ★ $20.27 | $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.57 | $12.99 |
| 52 Week High | $48.40 | $18.90 |
Technical Indicators
Market Signals| Indicator | RELX | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 45.59 | 64.39 |
| Support Level | $32.54 | $17.87 |
| Resistance Level | $35.73 | $18.85 |
| Average True Range (ATR) | 0.57 | 0.21 |
| MACD | -0.19 | -0.01 |
| Stochastic Oscillator | 23.20 | 84.66 |
Price Performance
Historical ComparisonAbout RELX RELX PLC PLC
RELX is a developer of information-based analytics and decision tools designed to support research, risk assessment, legal work, and business operations. The company offers data analytics, scientific and technical information resources, legal research tools, and event management platforms. This enables professionals, researchers, legal teams, and businesses to make informed decisions and improve operational efficiency.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.